

# THE VIEW

Life sciences | December 2020



Hi there,

As 2020 draws to a close, it's time to carefully review the new realities in life sciences that will pave the way for 2021 and beyond. Telemedicine, for one, had a remarkable year. Analysts suggest that it will continue to experience a growth rate of 40% through 2023. In this month's newsletter, we look at the technologies that will drive growth in telemedicine, before highlighting future trends across key segments.

## What's next in telemedicine?

The American Medical Association has estimated that 60% to 90% of clinicians started using some form of telehealth and telemedicine service since the pandemic's advent. Here's how AI, robotics, VR and other smart technologies are changing the face of telemedicine. >>



## How AI is revolutionizing EHR systems

The use of electronic health records (EHRs) helps clinicians work with speed and in a more organized manner. Let's take a look at how healthcare and technology firms are improving upon these systems and optimizing their productivity by using AI. >>

## Nanotechnology: changing healthcare's future

The use of nanotechnology is opening new frontiers across life sciences. It can revolutionize myriad aspects of medical care, including diagnostics, disease monitoring, surgical devices, regenerative medicine, vaccine development, and drug delivery. >>

## Trends to watch for in 2021

### Healthcare

- Virtual care and remote medicine
- Genome editing
- Fairer healthcare insurance and coverage

### Life sciences

- Personalized medicine
- Value-based care and products pricing
- Heightened focus on immune cell function

## Pharma

- Faster time-to-market for drug discovery
- Digitization and automation
- Emergence of biologics

## Digital health

- Expansion of telemedicine
- Use of VR, AI and wearables
- Digital health portals, hubs and big data

PWC

### 2021 M&A Outlook: poised for deals rebound

2020 was a slow year for M&As in life sciences with only USD 150B in deals, one of the lowest in the decade. However, according to PWC, 2021 will be a return to the normal with around USD 250B-275B in predicted deal activity. >>>

| Date announced | Target name                                    | Industry        | Acquirer full name                    | Value of transaction (\$billions) |
|----------------|--|-----------------|---------------------------------------|-----------------------------------|
| 1 9/13/2020    | ImmunoMedics, Inc.                             | Biotech         | Gilead Sciences, Inc.                 | 26.9                              |
| 2 8/22/2020    | Varian Medical Systems Inc.                    | Medical Devices | Siemens Healthineers                  | 17.2                              |
| 3 10/12/2020   | MyoCardia, Inc.                                | Pharma          | Bristol-Myers Squibb Company          | 13.1                              |
| 4 9/11/2020    | GRAIL, Inc.                                    | Biotech         | Bristol, Inc.                         | 8.0                               |
| 5 8/19/2020    | Microvet Pharmaceuticals, Inc.                 | Biotech         | Johnson & Johnson                     | 6.4                               |
| 6 3/23/2020    | Fifty Seven, Inc.                              | Biotech         | Gilead Sciences, Inc.                 | 5.0                               |
| 7 10/26/2020   | Astellas Pharma Inc.                           | Biotech         | Boehringer Ingelheim                  | 4.9                               |
| 8 8/11/2020    | Pharos Biopharma Inc.                          | Biotech         | Sandoz                                | 3.7                               |
| 9 1/15/2020    | Vividus, Inc.                                  | Biotech         | Merck & Co., Inc.                     | 2.8                               |
| 10 9/24/2020   | Takeda's Japanese Consumer Healthcare Business | Pharma          | Daiichi Sankyo Inc (Blackstone Group) | 2.3                               |

## Expert Views

### Healthtech Advisor

#### What's next for healthcare delivery? Nine medical experts predict

"AI-driven insurance or self-pay models that modulate individual patient care costs based on data acquired from IoT setup in our patients' home, will be the first system-wide change. AI and blockchains will drive 30-40% of the healthcare system." - Atif Zafar, Medical Director, St. Michael's Hospital >>>

### Becker's Health IT

#### Predictions for where digital health is heading in 2021

"2021 will be a year of realignment in digital health. Virtual care offerings would be differentiators in their competitive markets, with remote monitoring and digital therapeutics. Digital connectivity will be a social determinant of health." -

**Omkar Kulkarni, Chief innovation officer, Children's Hospital, L.A.** >>>

Netscribes helps life sciences firms build a competitive advantage through actionable data and insights. To schedule a consultation, [contact us](#)

Happy Holidays!



We value your feedback.

Please take this quick survey to help us serve you better insights

41 East, 11th Street, New York  
NY10003, USA  
+1-877-777-6569  
info@netscribes.com



Subscribe to our newsletter

This email was sent to {{ contact.EMAIL }}  
You received this email because you are registered with Netscribes

[Unsubscribe here](#)

© 2020 Netscribes